Delving into the Latest Updates on Nanjing Immunophage Biotech Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Immunophage Biotech is a pharmaceutical company based in China that specializes in the research and development of innovative medicines for the treatment of cancer, autoimmune diseases, and neurodegenerative disorders. The company was founded in 2016 and has its R&D center located in the Pujiang High-Tech Park in Shanghai. Their focus is on creating groundbreaking immune-regulating therapies that can improve patient outcomes.

Tags

Immune System Diseases

Skin and Musculoskeletal Diseases

Nervous System Diseases

Small molecule drug

Monoclonal antibody

Antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	9
Nervous System Diseases	7
Neoplasms	7
Endocrinology and Metabolic Disease	3

Top 5 Drug Type	Count

Small molecule drug	10
Monoclonal antibody	6
Antibody	2
Chemical drugs	1

Top 5 Target	Count

CCR8(C-C motif chemokine receptor 8)	3
GPR183(G protein-coupled receptor 183)	3
CD38(Lymphocyte differentiation antigen CD38)	2
CCR6(C-C motif chemokine receptor 6)	1
Hydrolase x NAD+	1

This is a phase 1, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) characteristics and initial anti-tumor activity of IPG1094 in patients with advanced solid tumors. The study will be conducted in two parts: dose escalation phase (Part A) and expansion phase (Part B).

Start Date20 Feb 2024

Sponsor / Collaborator

Nanjing Immunophage Biotech Co. Ltd.Startup

100 Clinical Results associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

2

Literatures (Medical) associated with Nanjing Immunophage Biotech Co. Ltd.

01 Jun 2023·Journal of Clinical Oncology

Development of a CCR8 monoclonal antibody to block CCR8 signaling and to abolish the immunosuppressive function of Treg for the treatment of cancers.

Author: Fan, Guohuang ; Zhang, Yuanyuan ; Wang, Zhilong ; Zhang, Yong ; Tian, Binle ; Wang, JianFei

e14506 Background: The tumor microenvironment (TME) contains regulatory T (Treg) cells, which play a critical role in immunosuppression and are thus an attractive target for cancer therapy. The ideal approach would be to inhibit Tregs within tumors while sparing those in peripheral and normal tissues. Tumor-associated Tregs express the chemokine receptor CCR8, which is involved in the induction, expansion, migration, and immunosuppression of Tregs, making targeted inhibition of CCR8 signaling a potential therapeutic strategy against cancer. Methods: We have developed IPG0521, a monoclonal antibody antagonist of CCR8, and characterized its properties, including signaling blocking, chemotaxis, species cross-reactivity, anti-tumor efficacy, and synergistic antitumor effect with PD1 antibody. Single-cell RNA sequencing with CD45+ cells isolated from tumors treated with or without IPG0521 was also employed for profiling the mechanism of the antitumor effect of IPG0521 in the murine H22 cancer model. Results: IPG0521 inhibits receptor-mediated signaling and chemotaxis in Treg cells with a single-digit nanomolar IC50. It is cross-reactive in five species: mouse, rat, dog, monkey, and human. IPG0521 has shown excellent anti-tumor efficacy in several murine syngeneic cancer models, and its anti-tumor effect is enhanced when combined with a PD-1 antibody. Its sustained anti-tumor efficacy has been demonstrated in the murine H22 cancer model via even withdrawing the antibody during the study. The results of deep single-cell RNA sequencing on tumor-infiltrating lymphocytes (TILs) showed that the transcriptional profiles of these Treg cells could be distinguished into three distinct subsets based on molecular, functional, and immunosuppressive properties. These subsets were defined as the Treg_Foxp3 high subset, which exhibited low immunosuppression, the Treg_Foxp3 mild subset, which demonstrated mild immunosuppression, and the Treg_Foxp3 low subset, which had high proliferation. IPG0521 treatment resulted in a significant increase in the Treg_Foxp3 high subset and a significant decrease in the Treg _Foxp3 mild subset while no change in the Treg_Foxp3 low subset, indicating a reduction in Treg immunosuppression. This change in Treg cells also altered the composition of other immune cells, including a significant increase in neutrophils and natural killer (NK) cells, which ultimately inhibited tumor growth. Conclusions: IPG0521 has potent anti-tumor effects in multiple tumor types, including lung, liver, and breast cancers, in both syngeneic and immune-humanized mouse models. It inhibits Tregs immunosuppression and activates CD8+ T cells to achieve its anti-tumor effects. These results support the development of IPG0521, which is currently under IND filing, as a novel therapeutic agent for the treatment of cancers.

04 Apr 2023·Cancer Research

Abstract 2340: Development of a CCR8 monoclonal antibody which blocks CCR8 signaling and abolishes the immunosuppressive function of Treg for the treatment of cancer

Author: Fan, Guohuang ; Wang, Na ; Zhang, Yuanyuan ; Tian, Binle ; Zhang, Yong ; Wang, Jianfei ; Jia, Xuebing

AbstractWithin the tumor microenvironment (TME), regulatory T (Treg) cells are one attractive cell type for targeting as they play a critical role in immunosuppression. Therapeutic strategies that specifically inhibit tumor-infiltrating Tregs while sparing peripheral and normal tissue Tregs are highly desirable. The tumor-associated Tregs express the chemokine receptor CCR8, which plays a role in the induction, expansion, chemotactic migration, and immunosuppression of tumor-associated Tregs. Thus, targeted inhibition of CCR8 is a potential therapeutic strategy against cancer. We have developed a monoclonal antibody antagonist of CCR8, IPG0521, which potently inhibited the receptor-mediated signaling and chemotaxis in Treg cells with single digital nanomolar IC50. RNA sequencing (RNA-seq)analysis indicated that CCL1-induced up-regulation of immunosuppressive genes, including PD-1, CTLA4, IL-10, TIGIT etc., were reversed by IPG0521 in tumor-derived Treg cells. IPG0521 potently inhibited the growth of multiple tumor types in both syngeinic and immune-humanized mouse models, including lung cancer, liver cancer, breast cancer, via inhibiting Treg and activating CD8+ T cells. These data pave the way for the development of IPG0521, which is under IND filing, as a novel therapeutic agent against cancer.Citation Format: Guohuang Fan, Jianfei Wang, Na Wang, Yuanyuan Zhang, Yong Zhang, Binle Tian, Xuebing Jia. Development of a CCR8 monoclonal antibody which blocks CCR8 signaling and abolishes the immunosuppressive function of Treg for the treatment of cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2340.

100 Deals associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

100 Translational Medicine associated with Nanjing Immunophage Biotech Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

10

4

Preclinical

IND Application

2

1

Phase 1 Clinical

Phase 2 Clinical

2

7

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

IPG-11406 ( GPCR )	Lupus Nephritis More	Phase 2
IPG-1094 ( MIF )	Lupus Nephritis More	Phase 2
IPG-7236 ( CCR8 )	Immunoglobulin G4-Related Disease More	Phase 1
IPG-8294 ( Hydrolase x NAD+ )	Amyotrophic Lateral Sclerosis More	IND Application
IPG0521 ( CCR8 )	Solid tumor More	IND Application